BioCentury

1:39 AM GMT, Jul 18, 2009
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical News

ACT-293987 meets Phase IIa endpoint

Actelion Ltd. (SIX:ATLN) said ACT-293987 met the primary

Read the full 87 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.